From Renal Biomarkers to Therapeutic Targets: The Use of Monocyte Chemoattractant Protein 1, Transforming Growth Factor-Beta, and Connective Tissue Growth Factor in Diabetic Nephropathy and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

• Main Authors: Katrina J Spensley, Frederick W. K. Tam
• Format: Article
• Language: English
• Published: European Medical Journal 2018-12-01
• Series: European Medical Journal
• Subjects: antineutrophil cytoplasmic antibody-associated vasculitis; biomarkers; connective tissue growth factor (ctgf); diabetic nephropathy; monocyte chemoattractant protein 1 (mcp-1); transforming growth factor-beta (tgf-β)
• Online Access: https://www.emjreviews.com/nephrology/article/from-renal-biomarkers-to-therapeutic-targets-the-use-of-monocyte-chemoattractant-protein-1-transforming-growth-factor-beta-and-connective-tissue-growth-factor-in-diabetic-nephropathy-and-antineutro/

In an ideal world, every condition would have a sensitive and specific marker that could be measured in a noninvasive or minimally invasive way. Instead, the medical community depends on invasive biomarkers, which carry inherent risks, to make a diagnosis and plan treatment. In this review article, the current state of research into biomarkers for a range of kidney diseases is discussed, beginning with those biomarkers that are already in clinical use and then moving to conditions for which no validated biomarker yet exists. This review focusses on diabetic nephropathy at the proteinuric end of the spectrum and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis at the nephritic end. An interesting feature is that the same biomarker, monocyte chemoattractant protein-1 (MCP-1, also known as CCL2), has been identified as a potential target in both conditions, which suggests a shared pathogenic process that results in two very distinct clinical presentations. One of the major limiting features of research into this area, particularly for ANCA-associated vasculitis, is the recruitment of a sufficient number of patients to generate strong enough evidence to justify the biomarker’s routine use; this overlap in biomarkers may enable research in one condition to be applied more generally. In addition to their role as biomarkers, these molecules are also therapeutic targets, and some early research has been carried out to investigate this. Overall, this review brings together research from diverse fields to focus attention on the outstanding areas and the future areas that warrant further investigation.